Your First SARMs Cycle: A Softer Alternative?

What SARMs are (and what they are not)

SARM = Selective Androgen Receptor Modulator. The principle is to stimulate the androgen receptor in target tissues (muscle, bone) while limiting action on other tissues (prostate, skin) ^[4]. In theory, that allows anabolic effects without the full side-effect load of a steroid. In practice, selectivity is never total and varies with the compound, dose and duration ^[3].

Regulatory status: SARMs are not approved for human use in most jurisdictions. They are sold as 'research chemicals', which puts the entire burden of quality control and dosing accuracy on the user. Clinical track record is significantly shorter than for steroids; long-term safety is still poorly characterized.

The most-used SARMs

• Ostarine (MK-2866): the most studied and best-tolerated, usually the first SARM people try.
• LGD-4033 (Ligandrol): the most anabolic, marked suppression ^[1].
• RAD-140 (Testolone): potent, with suppression comparable to low-dose steroids ^[5].
• MK-677 (Ibutamoren): not technically a SARM but a GH secretagogue; no HPTA suppression.

What to realistically expect

For most users at contained doses, SARMs deliver: a clear recomposition (moderate muscle gain, slight fat loss), better recovery, and rising strength — without the marked water retention of a steroid cycle. Absolute gains are smaller than an equivalent testosterone-only cycle, but the immediate side-effect profile is often perceived as lighter.

What you should not expect: dramatic gains in a few weeks, no side effects whatsoever, or zero hormonal cost. The most-shared SARMs before/after pictures usually involve stacks of multiple SARMs at high doses, sometimes with other compounds — that is not the profile of a 'soft first cycle'.

HPTA suppression: variable, but real

The most stubborn myth is "SARMs do not suppress". False. Suppression depends on the compound, the dose and the duration. The most anabolic SARMs — LGD-4033, RAD-140 — produce marked suppression, sometimes comparable to a low steroid dose ^[1]. Ostarine is gentler but still suppresses past roughly 25 mg/day or on long cycles ^[2].

The "cycle without PCT" idea is therefore wrong for most SARMs. For LGD-4033 and RAD-140, the reference protocol is a standard PCT on Nolvadex, typically 40/40/20/20 mg/day over 4 weeks. For Ostarine at a contained dose, a mini-PCT (Nolvadex 20 mg/day × 4 weeks) can be enough — but only bloods decide. The SARMs PCT guide breaks down the trade-offs.

Side effects: different, not absent

SARMs share part of the steroid side-effect profile (suppression, post-cycle fatigue, lipid impact) while bringing their own: mild vision changes on Ostarine, irritability on RAD-140, moderate liver signals on some compounds at high doses ^[1]. The long-term cardiovascular profile is poorly characterized for lack of follow-up ^[3].

• HPTA suppression: present on most anabolic SARMs.
• Lipid panel: HDL often drops, especially on long cycles.
• Liver: moderate AST/ALT signals on some compounds at high doses.
• Vision: transient variations possible on Ostarine.
• Long term: limited clinical track record, vigilance warranted.

Blood work keeps all of its value: baseline before, mid-cycle check, and a post-PCT panel to confirm recovery. See the blood work on cycle guide for panels.

SARMs or testosterone on a first cycle: the honest comparison

Neither is harmless. Testosterone is better documented, side effects are known, protocols are rehearsed; the downside is injecting twice weekly and full suppression. SARMs have a simpler route, often milder immediate effects, but a shorter clinical track record, real suppression, and a market that is even less reliable.

The pick depends on priorities. For a beginner who wants 'the best-known profile', it is testosterone only. For a beginner who values an oral route and a moderate recomposition, Ostarine at a contained dose is the most defensible option — with a blood panel and a planned PCT, like any other cycle.

Frequently asked questions